[HIV infection 2007].
There is hardly any other medical field that has experienced changes and developments as dramatic as in the treatment of HIV infection in the last years. In Germany, 19 antiretroviral substances have been approved. New substances are effective in multidrug resistance viruses. The classes of CCR5 receptor antagonists and integrase inhibitors are new therapeutic options for heavily pretreated patients. In spite of this success many problems remain unsolved, e.g., lipodystrophy, osteoporosis, cardiovascular diseases and an increased number of tumors. Once more, the ideal point of treatment initiation needs to be discussed. Treating early prevents new infections and improves the course of HIV infection.
Potthoff
Anja
A
Klinik für Dermatologie und Allergologie der Ruhr-Universität Bochum, St. Josef-Hospital, Bochum, Germany.
Brockmeyer
Norbert
N
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D065100:CCR5 Receptor Antagonists; D015897:Comorbidity; D017277:Drug Approval; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008403:Mass Screening; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology; D009894:Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists